Covers a case report of therapy-related acute myeloid leukemia developing two years after CAR-T therapy, with longitudinal genomic evolution documented.
Key Takeaways
- 65-year-old DLBCL patient developed therapy-related AML 24 months after initial CD19 CAR-T therapy
- Next-generation sequencing showed TP53 was wild-type at lymphoma diagnosis and later progressed to biallelic TP53 loss
- Cytogenetics revealed a complex karyotype including del(5q)